

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **THE GROUP'S PRODUCT ROXITHROMYCIN CAPSULES PASSED THE CONSISTENCY EVALUATION**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Roxithromycin Capsules (specification: 150mg) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, passed the consistency evaluation of quality and efficacy for generic drugs ("Consistency Evaluation") which was approved by China National Medical Products Administration.

Roxithromycin Capsules are second-generation macrolide antibiotics with notable anti-infective advantages, including good acid stability, a broad antibacterial spectrum, strong tissue penetration, and a relatively low incidence of adverse reactions. They are clinically indicated for the treatment of infections of the ear, nose and throat, respiratory tract, skin and soft tissues, and the genitourinary tract caused by pathogens susceptible to roxithromycin. Currently, Roxithromycin Capsules have been listed in the Category B in the National Medical Insurance Drug List (2025 Edition). The Company is the first enterprise to have passed the Consistency Evaluation for the Roxithromycin Capsules dosage form.

This approval will further solidify the Company's leading position in the anti-infective field. In the future, the Company will continue to devote itself to the research and development of new products, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 9 February 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.